Xenetic Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Xenetic Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 74% in 3 years; of every extra $100 of sales, $305 became extra profit. Higher than 90% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$305Sales grew 74% in 3 years; of every extra $100 of sales, $305 became extra profit.
Higher than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+74% / -43%In 3 years sales changed by +74% while total assets changed by -43%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Xenetic Biosciences, Inc. made a loss over the last year. Xenetic Biosciences, Inc. owes $0.13 for every $1 it owns. Xenetic Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossXenetic Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.74The share price is 0.74 times Xenetic Biosciences, Inc.'s book value per share, lower than 85% of Healthcare companies in United States.
Market cap
$5 MThe total market value of all of Xenetic Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$6 MWhat Xenetic Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.59Net worth divided by the number of shares. The share price of $1.93 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-47.0%Xenetic Biosciences, Inc. lost 47.0% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
Owes vs Owns
0.13×Xenetic Biosciences, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneXenetic Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+19%Revenue rose 19% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Profit growth
LossXenetic Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-90.1%Xenetic Biosciences, Inc. lost $90 for every $100 of revenue.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Xenetic Biosciences, Inc.: $5 M ÷ $6 M (30 Jun 2026) = 0.7.
What is Xenetic Biosciences, Inc.'s return on equity?
Xenetic Biosciences, Inc. lost 47.0% of its shareholders' money over the last year, higher than 51% of Healthcare companies in United States.
How much does Xenetic Biosciences, Inc. owe compared with what it owns?
Xenetic Biosciences, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Xenetic Biosciences, Inc. pay a dividend?
No. Xenetic Biosciences, Inc. does not currently pay a dividend.
Is Xenetic Biosciences, Inc.'s revenue growing?
Revenue rose 19% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.